About
Technology
Issues
FAQ
Links
Official Page
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.